Quest Diagnostics is building out its artificial intelligence-powered cancer pathology offerings through a multilayered deal with PathAI—acquiring some assets and licensing out others. The testing ...
In the most traditional definition of return-on-investment, Sam Terese, former CEO and president of Alverno Laboratories, would say that his company isn’t experiencing a strict apples-to-apples ...
CyPath® Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic market by 2034Precision Pathology Laboratory Services meets gold standard for excellence across all ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback